New sales opportunities for Vitrolife in China

New sales opportunities for Vitrolife in China  

Vitrolife is establishing a sales office in Beijing, China, in line with the
strategy of operating under its own management in key markets. The Chinese
market for In Vitro Fertilization is the third largest in the world in terms of
the number of treatments, and is rapidly growing.  

Vitrolife is the market leader in the IVF media business in China. During the
last few years we have more than doubled the turnover and are continuously
growing. In order to strengthen our position as the dominant actor in the market
in the country, it is logical to set up the company's own sales office in China.
“With the local presence in the market, we will improve our relations with
customers and regulatory authorities as well as improve logistics for the end
customers, and in a larger context setting up in China will mean a great deal
for increasing Vitrolife's opportunities for more rapid development in all of
Asia”, says Vitrolife's VP Marketing & Sales Nils Sellbom. 

The Chinese sales office will be headed by Dr. Joe Zhengzhu Jin, who has played
a large part at Vitrolife in building up the company's already strong position
in the Chinese market. 

“I see the establishment of the sales office as an important step in continuing
to develop our market development in China, as it gives us better opportunities
to give technical support and service direct to our customers and partners
there,” says Dr. Jin.


April 1, 2009
Gothenburg, Sweden 

Magnus Nilsson
CEO




Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 61


________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 150 employees and the company's products
are sold in more than 80 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France and Italy.
Production facilities are housed in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.